The acquisition will include full-automatic nucleic acid analysis equipment for use by HUSLAB and the Eastern Finland Laboratory Group (ISLAB) units and the purchase of equipment supplies. Hardware is acquired for use by units as follows: Two four-seat hardware becomes available to HUSLAB. Four two-seater hardware will be available to ISLAB (2 pieces to Kuopio, 1 piece to Joenmouth and 1 piece to Mikkeli). All procurement will be completed during 2021. In full automatic nucleic acid analysis equipment that will be used by HUSLAB units, there should be four (4) pieces of device modules. For nucleic acid isolation and analysis devices that come into use of ISLAB units, there should be two (2) pieces of device modules.

The acquisition includes an option option option option option (see section II.2.2.11). The bidder undertakes to supply the optional hardware at the same price and on the same terms as the actual equipment being acquired.

Procurement of the acquired equipment is aimed at rapid PCR diagnostics of positive blood cultures, liquid and airway samples directly from the sample to units of HUSLAB and ISLAB. The acquisition involves competition of device-linked reagents with equipment to detect blood cultures and detection of respiratory, central nervous system, and faecal pathogens. The tests shall be CE IVD-marked, as well as tests approved by the equipment manufacturer. The test price shall include test kittes, reagents, test-specific software, shipping costs and product support required to conduct the test.

Nucleic acid analysis equipment that is subject to acquisition should be full automated tomatoes and suitable for quick-call diagnostics. Full-automatic nucleic acids analysis equipment shall enable the isolation and analysis of blood culture, upper respiratory, spinal fluid and faecal samples as starting materials. The equipment that is acquired shall allow the processing of all the output materials presented above. In addition, the acquired device should allow simultaneous testing of bacteria, viruses, yeast, parasites and antimicrobial resistant genes.

In addition to the above equipment acquisition, test cartridges required to operate fully automatic nucleic acid analysis equipment are subject to the acquisition. The test cartridges subject to acquisition shall be explicitly compatible with the nucleic acid isolation and analysis equipment provided for in the Vendor Offer. Acquired sample cartridges are sourced as required by the Procurement Unit. Annual sample volumes for contracting entities are estimated at:

- Blood culture panel: 5500 pcs/v (Helsinki) ,150 pcs/v (Lappeenranta), 2300 pcs/v (ISLAB)

- CNS panel: 1.000 pcs/v (Helsinki), 400 pcs/v (ISLAB)

- Respiratory panel: 1.700 pcs/v (Helsinki), 280 pcs/v (Lappeenranta), 500 pcs/v (ISLAB)

- Fecal panel: 1.000 pcs/yr (Helsinki)

The annual sample volumes set out above are estimates only and the Procurement Entities do not commit to an order in accordance with the estimated sample volumes. So it is possible, for example, that some unit/units will not acquire a sample cartridge at all, or that sample cartridges will be acquired more than estimates.

As a result of the procurement procedure, one (1) Vendor is selected with whom an indefinite contract is awarded. The full automatic nucleic acid analysis equipment subject to acquisition must be delivered and invoiced during 2021. A more detailed delivery schedule will be agreed later between Subscriber and Vendor.

Description of the object of the acquisition as set out above.